The Medical Advisor

Medically Reviewed by: Dr Frank Yap, MD | Written by: OneDayMD Editorial Team | Last Updated: November 2026 | Originally Published: January 2026 There has been no shortage of claims that artificial intelligence (AI) will cure cancer and other diseases that remain difficult or impossible to cure. But how much of this is scientific progress, and how much is hype? Where do we actually stand? This comprehensive, evidence-graded hub examines the state of AI, systems biology, and digital health in preventive medicine, oncology, and longevity science as of November 2026.  It separates technologies that are FDA-authorized, clinically validated, or supported by meaningful human evidence from those that remain in early-stage research, pilot programs, or experimental development. The goal is not to dismiss AI's potential or exaggerate its capabilities, but to examine what it can demonstrably do today, where it is beginning to change clinical practice, and what still needs to...

Executive Summary Dr. Thomas N. Seyfried , Professor of Biology at Boston College, proposes a metabolic model of cancer that challenges the dominant genetic explanation and conventional oncology treatments. Rather than viewing cancer as primarily driven by gene mutations, Seyfried asserts it is fundamentally a metabolic disease centered on dysfunctional cellular energy production. This reframing draws on and expands the historical Warburg effect , emphasizing how cancer cells rely on fermentative metabolism of glucose and glutamine due to defective mitochondrial function.  A 2026 large-scale population study published in Nature Communications demonstrated that machine learning-predicted insulin resistance was associated with increased risk of 12 cancer types in nearly 500,000 individuals from the UK Biobank. This finding strengthens a growing thesis: Metabolic dysfunction is not merely a comorbidity —...